Nintedanib：大腸癌治療薬市場分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Clinical Staging 15
3.3 Symptoms 16
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Screening and Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.1.3 Clinical Practice 25
5 Competitive Assessment 32
5.1 Overview 32
6 Unmet Need and Opportunity 34
6.1 Overview 34
6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients 35
6.2.1 Unmet Need 35
6.2.2 Gap Analysis 37
6.2.3 Opportunity 37
6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients 39
6.3.1 Unmet Need 39
6.3.2 Gap Analysis 40
6.3.3 Opportunity 40
6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 41
6.4.1 Unmet Need 41
6.4.2 Gap Analysis 42
6.4.3 Opportunity 42
6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients 43
6.5.1 Unmet Need 43
6.5.2 Gap Analysis 43
6.5.3 Opportunity 44
7 Pipeline Assessment 45
7.1 Overview 45
7.2 Promising Drugs in Clinical Development 46
8 Nintedanib (BIBF-1120) 48
8.1 Overview 48
8.2 Efficacy 49
8.3 Safety 49
8.4 Dosing and Formulation 50
8.5 Potential Clinical and Commercial Positioning 50
8.6 SWOT Analysis 51
8.7 Forecast 51
9 Appendix 52
9.1 Bibliography 52
9.2 Abbreviations 57
9.3 Methodology 61
9.4 Forecasting Methodology 61
9.4.1 Diagnosed Colorectal Cancer Patients 61
9.4.2 Percent Drug-Treated Patients 62
9.4.3 General Pricing Assumptions 62
9.4.4 Average Body Weight and Surface Area Across the 8MM 63
9.4.5 Generic Erosion 63
9.4.6 Pricing of Pipeline Agents 63
9.5 Primary Research – KOLs Interviewed for this Report 64
9.6 Primary Research – Prescriber Survey 66
9.7 About the Authors 67
9.7.1 Analyst 67
9.7.2 Global Head of Healthcare 68
9.8 About GlobalData 69
9.9 Disclaimer 69